Early treatment of COVID-19 patients with hydroxychloroquine and azithromycin: A retrospective analysis of 1061 cases in Marseille, France
- 1 May 2020
- journal article
- research article
- Published by Elsevier BV in Travel Medicine and Infectious Disease
- Vol. 35, 101738
- https://doi.org/10.1016/j.tmaid.2020.101738
Abstract
No abstract availableFunding Information
- Agence Nationale de la Recherche
This publication has 21 references indexed in Scilit:
- Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in ChinaJAMA, 2020
- In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)Clinical Infectious Diseases, 2020
- Novel coronavirus infection during the 2019–2020 epidemic: preparing intensive care units—the experience in Sichuan Province, ChinaIntensive Care Medicine, 2020
- Nextstrain: real-time tracking of pathogen evolutionBioinformatics, 2018
- Azithromycin Inhibits the Replication of Zika VirusJournal of Antivirals & Antiretrovirals, 2018
- Simultaneous UHPLC-UV analysis of hydroxychloroquine, minocycline and doxycycline from serum samples for the therapeutic drug monitoring of Q fever and Whipple’s diseaseJournal of Chromatography B, 2017
- Zika virus cell tropism in the developing human brain and inhibition by azithromycinProceedings of the National Academy of Sciences of the United States of America, 2016
- Evaluation of Ebola Virus Inhibitors for Drug RepurposingACS Infectious Diseases, 2015
- Treatment of classic Whipple's disease: from in vitro results to clinical outcomeJournal of Antimicrobial Chemotherapy, 2013
- Hexadecyloxypropyl-cidofovir, CMX001, prevents adenovirus-induced mortality in a permissive, immunosuppressed animal modelProceedings of the National Academy of Sciences of the United States of America, 2008